Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.

17 Mar 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.

13 Mar 2016

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

A research team of the Comprehensive Cancer Center of MedUni Vienna and AKH Vienna was able to demonstrate that a therapy change in the area of metastasising renal cell carcinoma significantly increases the life average expectancy and clearly improves the compatibility of the therapy.

9 Mar 2016

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).

7 Mar 2016

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL).

4 Mar 2016

Pregnant women with acute migraine more likely to experience adverse birth outcomes

Women who have acute migraine attacks that are severe enough to prompt them to seek care may be more likely to have complications when giving birth, including preterm delivery, preeclampsia and low birthweight. Women 35 and older were seven times more likely to have these complications.

4 Mar 2016

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

More than two-thirds of all type-2 diabetes patients do not achieve good control of their disease with the first-line medication metformin combined with second-line insulin shots.

2 Mar 2016

Cardiac drug combats muscle cramps in ALS

A phase II study shows that the sodium channel blocker mexiletine has no specific safety concerns in patients with amyotrophic lateral sclerosis and, moreover, markedly reduces muscle cramps.

1 Mar 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

23 Feb 2016

Briviact (brivaracetam) approved for treatment of partial onset seizures in patients with epilepsy

The U.S. Food and Drug Administration yesterday approved Briviact (brivaracetam) as an add-on treatment to other medications to treat partial onset seizures in patients age 16 years and older with epilepsy.

22 Feb 2016

FDA-approved Alzheimer's medications may help people quit smoking

Despite several safe drug therapies available to help smokers quit, three-quarters report relapsing within six months of a quit attempt. University of Pennsylvania researchers Rebecca Ashare and Heath Schmidt saw potential for a permanent cessation solution in a class of FDA-approved medications used to improve cognitive impairments from Alzheimer's disease.

19 Feb 2016

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil).

16 Feb 2016

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that VIVLODEX (meloxicam) capsules, a nonsteroidal anti-inflammatory drug (NSAID), is now available by prescription at pharmacies across the United States.

16 Feb 2016

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

Amgen today announced that Kyprolis in combination with lenalidomide and dexamethasone is now available in the UK for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

16 Feb 2016

Worsening migraine no reason to halt dihydroergotamine infusion

Worsening of headache during intravenous dihydroergotamine treatment for chronic migraine does not mean that the therapy will be unsuccessful, say researchers.

12 Feb 2016

Atypical heart attack symptoms lead to delayed treatment, increased injury in women

When having a heart attack, most people will experience some kind of chest pain or pressure that worsens. Pain and pressure, along with sweating, shortness of breath and pain that migrates into the arms or neck are the typical heart attack symptoms.

12 Feb 2016

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

A clinical trial of an experimental drug for treatment-resistant major depression finds that modulation of the endogenous opioid system may improve the effectiveness of drugs that target the action of serotonin and related monoamine neurotransmitters.

12 Feb 2016

Nausea News and Research

Further Reading

MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

Pregnant women with acute migraine more likely to experience adverse birth outcomes

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

Cardiac drug combats muscle cramps in ALS

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Briviact (brivaracetam) approved for treatment of partial onset seizures in patients with epilepsy

FDA-approved Alzheimer's medications may help people quit smoking

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

Worsening migraine no reason to halt dihydroergotamine infusion

Atypical heart attack symptoms lead to delayed treatment, increased injury in women

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News